doi: 10.9745/GHSP-D-16-00226; Glob Health Sci Pract December 23, 2016 vol. 4 no. 4 p. 626-646
BMC Public Health (2018) 18:668 https://doi.org/10.1186/s12889-018-5594-3
Joint WHO/ILO guidelines on post-exposure prophylaxis (PEP) to prevent HIV infection.
Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection
Accessed: 26.02.2020
Guidelines
HIV testing services
July 2015
While much progress has been achieved over the past year, the Region of the Americas has stubbornly remained the epicenter of the COVID-19 pandemic. PAHO is launching its 2021 COVID-19 Response Strategy and Donor Appeal to continue supporting Latin American and Caribbean countries and territories i...n their fight against COVID-19. This document outlines PAHO’s regional strategy for the year 2021 to sustain and scale-up the response to COVID‑19 pandemic in the Americas, suppress the community transmission of the virus and mitigate the longer-term health impact of the pandemic.
US$ 239 million is needed to support critical response efforts in the Americas between 1 January and 31 December 2021
more
The Kenya Strategic AIDS Framework IV prioritises key populations for interventions
This report provides the context, underlying evidence, content and process related to the
development of the draft global strategic directions for nursing and midwifery 2021–2025.
Afr J Thoracic Crit Care Med 2021;27(4):Published online 22 October 2021. https://doi.org/10.7196/AJTCCM.2021.v27i4.173
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health sys...tems to anticipate and mitigate stresses across NCD medicine supply chains. The full range of upstream and downstream impacts are investigated, including: manufacturing; procurement, importation and last mile delivery; patient-level effects through affordability and availability; and the effects on NCD medicine availability by category of disease. The report culminates in recommended actions and interventions for key stakeholders in the NCD pharmaceutical supply chain, including governments, regulatory authorities, manufacturers and the private sector; as well as directions for future research for improving access and supply chain access resilience.
more